دورية أكاديمية
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib : post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)
| العنوان: | Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib : post hoc analysis of the CORRECT phase III trial (RadioCORRECT study) |
|---|---|
| المؤلفون: | Ricotta, Riccardo, Verrioli, Antonella, Ghezzi, Silvia, Porcu, Luca, Grothey, A., Falcone, Alfredo, Van Cutsem, Eric, Argiles, Guillem, Adenis, Antoine, Ychou, Marc, Barone, Carlo, Bouche, Olivier, Peeters, Marc, Humblet, Yves, Mineur, Laurent, Sobrero, Alberto F., Hubbard, Joleen M., Cremolini, Chiara, Prenen, Hans, Tabernero, Josep, Jarraya, Hajer, Mazard, Thibault, Deguelte-Lardiere, Sophie, Papadimitriou, Konstantinos, Van den Eynde, Marc, Pastorino, Alessandro, Redaelli, Daniela, Bencardino, Katia, Funaioli, Chiara, Amatu, Alessio, Carlo-Stella, Giulia, Torri, Valter, Sartore-Bianchi, Andrea, Vanzulli, Angelo, Siena, Salvatore |
| المصدر: | 2059-7029 ; ESMO Open |
| سنة النشر: | 2016 |
| المجموعة: | IRUA - Institutional Repository van de Universiteit Antwerpen |
| الوصف: | Objective To identify imaging markers predicting clinical outcomes to regorafenib in metastatic colorectal carcinoma (mCRC). Methods The RadioCORRECT study is a post hoc analysis of a cohort of patients with mCRC treated within the phase III placebo-controlled CORRECT trial of regorafenib. Baseline and week 8 contrast-enhanced CT were used to assess response by RECIST 1.1, changes in the sum of target lesion diameters (Delta STL), lung metastases cavitation and liver metastases density. Primary and secondary objectives were to develop ex novo univariable and multivariable models to predict overall survival (OS) and progression-free survival (PFS), respectively. Results 202 patients were enrolled, 134 (66.3%) treated with regorafenib and 68 (33.7%) with placebo. In the univariate analysis, PFS predictors were lung metastases cavitation at baseline (HR 0.50, 95% CI 0.27 to 0.92, p=0.03) and at week 8 (HR 0.58, 95% CI 0.36 to 0.93, p=0.02). Baseline cavitation (HR 0.23, 95% CI 0.08 to 0.66, p=0.007), RECIST 1.1 (HR 0.23, 95% CI 0.14 to 0.4, p < 0.0001) and.STL (HR 1.16, 95% CI 1.06 to 1.27, p=0.002) predicted OS. We found an increase of 9% of diameter as the best threshold for discriminating OS (HR 2.64, 95% CI 1.61 to 4.34, p < 0.001). In the multivariate analysis, baseline and week 8 cavitation remained significant PFS predictors. Baseline cavitation, RECIST 1.1 and.STL remained predictors of OS in exploratory multivariable models. Assessment of liver metastases density did not predict clinical outcome. Conclusions RECIST 1.1 and.STL predict favourable outcome to regorafenib. In contrast to liver metastases density that failed to be a predictor, lung metastases cavitation represents a novel radiological marker of favourable outcome that deserves consideration. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/isi/000408009400007 |
| الإتاحة: | https://doi.org/10.1136/ESMOOPEN-2016-000111Test https://hdl.handle.net/10067/1458030151162165141Test https://repository.uantwerpen.be/docman/irua/079741/145803.pdfTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.C637644D |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |